2 Reasons to Buy AbbVie Stock, and 1 Reason to Sell
With 2021 net revenue estimated at $56.2 billion, AbbVie (NYSE: ABBV) is one of the world's most successful pharmaceutical companies. And given its massive pipeline of late-stage, drug-development programs in immunology, oncology, and aesthetics, the company likely has the opportunity to keep growing at a steady pace for years regardless of what's going on in the market or the economy.
But no stock is without flaws, and it behooves investors to understand both a company's strengths and weaknesses. Let's take a peek at two compelling reasons to buy the shares of AbbVie and one significant reason it might be better to avoid or sell -- so that you'll know whether any potential tribulations in the near future are worth the potential upside down the road.
Image source: Getty Images.
Source Fool.com
